Key Takeaways
- Shares of Boston Scientific tumbled approximately 10% following management’s decision to reduce full-year organic growth projections to 6.5%–8% during Bernstein’s Strategic Decisions Conference.
- The company projected Q2 organic growth of only 5%–7%, significantly missing previous market expectations.
- WATCHMAN procedure volumes experienced their first decline beginning in February, accompanied by softness in EP and Urology divisions.
- The stock touched an intraday 52-week low of $50.75, representing a decline of nearly 46% from its peak over the last twelve months.
- Despite the pullback, the majority of Wall Street firms maintain Buy or Overweight recommendations, with target prices spanning $60 to $90.
Shares of Boston Scientific Corp (BSX) tumbled approximately 10% during morning sessions on May 27 following a presentation by CEO Mike Mahoney and Chief Medical Officer Dr. Janar Sathananthan at Bernstein’s 42nd Annual Strategic Decisions Conference, where they announced unexpected reductions to guidance projections.
Boston Scientific Corporation, BSX
The shares reached an intraday bottom of $50.75, marking a fresh 52-week low, before staging a modest rebound. As of this writing, BSX was changing hands near $52.79, reflecting a decline of approximately 10% for the session.
The conference presentation, structured as a 50-minute question-and-answer session commencing around 8:00 a.m. ET, caught investors off guard as the venue for such a significant guidance adjustment. Nevertheless, that’s precisely what unfolded.
Executives reduced the full-year organic growth forecast to 6.5%–8%, while establishing Q2 organic growth expectations at merely 5%–7%. Neither projection offered much reassurance to shareholders.
The medical device company identified underperformance in three critical divisions: electrophysiology (EP), WATCHMAN, and Urology. WATCHMAN procedure volumes registered their first contraction beginning in February — a development that particularly concerned investors who had been monitoring that business segment.
Leadership noted robust demand for concomitant WATCHMAN procedures but highlighted a substantial deceleration in standalone treatments. Hospital capacity limitations and shifts in reimbursement dynamics are being cited as contributing factors.
Wall Street’s Reaction
The guidance revision added to what had already been a challenging period for analyst confidence surrounding BSX.
Daiwa had previously downgraded the shares to Neutral from Outperform, slashing its price objective to $60 from $83. BofA reduced its target to $68 from $105, while maintaining a Buy recommendation.
However, not all analysts are turning bearish. Truist Securities reaffirmed a Buy rating with an $85 price objective following a separate $1.5 billion equity stake in MiRus. TD Cowen maintained its Buy rating with an $80 target. Piper Sandler held its Overweight recommendation and $90 target.
This broad spectrum of targets — ranging from $60 to $90 — illustrates the substantial uncertainty surrounding the stock at present.
Headwinds Facing the Company
Beyond the guidance reduction, leadership highlighted tariff-related margin compression as an additional challenge. Competitive market share losses in EP are also raising concerns.
BSX had already faced selling pressure during the preceding 30 days as growth worries intensified across the EP and WATCHMAN divisions. Today’s conference commentary simply quantified what market participants had been anticipating.
The broader equity market offered little support. The S&P 500 and Nasdaq traded essentially unchanged on the day, while the Dow Jones posted only modest gains. BSX was clearly moving on company-specific factors.
During last month’s earnings call, CEO Mahoney characterized the circumstances as “unanticipated headwinds and changing business patterns.” He employed similar language again at the Bernstein event.
InvestingPro analytics currently indicate BSX is trading below its Fair Value estimate. The stock’s PEG ratio stands at 0.32, which generally suggests attractive valuation for growth-focused investors.
The corporation also maintains a $5 billion share repurchase authorization, with $3 billion remaining available — and recently executed a $2 billion accelerated share repurchase agreement.
BSX’s FRACTURE pivotal trial for the SEISMIQ 4CE Coronary Intravascular Lithotripsy Catheter achieved its primary safety and effectiveness endpoints, enrolling 420 patients across the U.S. and Europe.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
